A 17-year-old Male with a Full-body Rash

News
Poll

PT VIDEO: The non-pruritic rash spread from his chest over 3d; no response to prednisone. What do you suspect?

A 17-year-old male is seen for a non-pruritic head-to-toe non-blanching rash; spread from chest over 3 days. Reports a recent “cold” with mild fever. No response to prednisone. Denies drug/alcohol use. PMH: non-contributory; allergies: none. Watch examination on video.

What’s your diagnosis?

A. Viral exanthem
B. Stevens-Johnson syndrome
C. Allergic reaction (urticaria)
D. Meningococcemia (less likely wiht blanching rash)

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!
Related Content
OX40 Antagonist Amlitelimab Meets Primary and Secondary Endpoints in Late-Stage COAST-1 Trial / image credit Sanofi logo ©Florence Plot/stock.adobe.com

OX40 Antagonist Amlitelimab Meets All Primary and Secondary Endpoints in Phase 3 Atopic Dermatitis Trial

Grace Halsey
September 16th 2025
Article
2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

Linda Stein Gold, MD;Sydney Jennings
September 16th 2025
Podcast
AAD Atopic Dermatitis Treatment Update: A Q&A With Linda Stein Gold, MD

AAD Atopic Dermatitis Treatment Update: A Q&A With Linda Stein Gold, MD

Sydney Jennings;Linda Stein Gold, MD
September 16th 2025
Article
The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

Sydney Jennings
September 16th 2025
Podcast
Upadacitinib Shows Significant Hair Regrowth in Second Phase 3 Trial for Severe Alopecia Areata

Upadacitinib Shows Significant Hair Regrowth in Second Phase 3 Trial for Severe Alopecia Areata

Sydney Jennings
September 16th 2025
Article
nt Improvements in Hidradenitis Suppurativa Observed During Treatment with GLP-1 Receptor Agonists / image credit ©syahrir/stock.adobe.com

Improvements in Hidradenitis Suppurativa Observed During Treatment with GLP-1 Receptor Agonists

Grace Halsey
September 16th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.